Roche’s Tecentriq combo wins fast FDA review in race to catch rivals
ZURICH (Reuters) – Roche’s immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday. Roche ... More »
